ImmunoGen shares tank (again) after the FDA nixes a shot at an OK for its armed antibody in wake of a failed PhIII
ImmunoGen $IMGN just compounded its woes with their lead drug.
Two months after acknowledging that their antibody-drug conjugate mirvetuximab soravtansine failed a Phase III study for ovarian cancer, the FDA has batted back an attempt to hunt an accelerated approval based on a secondary endpoint, sending their stock price tumbling again.
The FDA now wants to see a new Phase III trial for the drug, which won’t be cheap or easy to pull off.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
